Aurora Cannabis Inc. (CSE:ACB,FWB:21P,OTCQB:ACBFF) reported that the company has surpassed 7,700 active registered patients in under eight months after the first sale of product. The company also announced that gross revenue for the month of August was $1.2 million.
As quoted in the press release:
The Company’s production facility has just completed a substantial upgrade and expansion of its mother room, with the addition of full-spectrum LED + HID lighting and an automated irrigation system that can deliver cultivar-specific nutrient formulas. The improvements effectively double the room’s plant capacity and further strengthen Aurora’s commitment to full lifecycle plant health and quality.
“I am delighted with our operational performance, our proprietary technologies, and our ability to execute our goals with discipline and vision. The Aurora Standard continues to elevate the way patient needs are being met across Canada,” said Terry Booth, CEO.
Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical marijuana pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada. Aurora trades on the Canadian Securities Exchange under the symbol “ACB”.